How to measure the long-term value of GLP-1s within employer healthcare costs
HFMATopic alignment 92
Employers are facing a difficult balancing act. GLP-1 medications offer significant opportunities to improve employee health, particularly for individuals living with obesity, diabetes and related chronic conditions. Yet their growing utilization is adding substantial costs to employer-sponsored health plans, often before the associated medical savings become apparent. According to the Business Group on Health’s 2026… The post How to measure the long-term value of GLP-1s within employer healthca
Filed under
- GLP-1 cost managementmatch 92
- Employer pharmacy strategymatch 85
Medicare Plans Rarely Cover Anti-Obesity Drugs for Other FDA-Approved Purposes
USC SchaefferTopic alignment 95
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
MedCity NewsTopic alignment 86
#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
Endpoints NewsTopic alignment 86
EqualityGLP-1 Weight-Loss Drugs Will Be Covered for Fewer US EmployeesJust 53% of US employers now cover GLP-1s for weight loss, and nearly a third of those still offering the benefit are considering dropping it.Read more
BloombergTopic alignment 90